January 14, 2021
Daiichi Sankyo said on January 13 that its sakigake -designated Duchenne muscular dystrophy (DMD) treatment DS-5141 demonstrated efficacy in several patients in a Japanese PI/II trial for the drug, which is being jointly developed with the Orphan Disease Treatment Institute...read more